Home Cart Sign in  
Chemical Structure| 781613-23-8 Chemical Structure| 781613-23-8
Chemical Structure| 781613-23-8

Tesevatinib

CAS No.: 781613-23-8

XL647 or tesevatinib inhibits EGFR, HER2, VEGFR and EphB4 with potential antineoplastic activity.

Synonyms: EXEL-7647; XL647; KD-019

4.5 *For Research Use Only !

Cat. No.: A100327 Purity: 99%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÿó¶ÊÊ Inquiry Inquiry
2mg łóò¶ÊÊ Inquiry Inquiry
5mg łÇÍÿ¶ÊÊ Inquiry Inquiry
10mg łËÍó¶ÊÊ Inquiry Inquiry
25mg łÍîÿ¶ÊÊ Inquiry Inquiry
50mg łóÍ˶ÊÊ Inquiry Inquiry
100mg łÇͧǶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÿó¶ÊÊ

  • 2mg

    łóò¶ÊÊ

  • 5mg

    łÇÍÿ¶ÊÊ

  • 10mg

    łËÍó¶ÊÊ

  • 25mg

    łÍîÿ¶ÊÊ

  • 50mg

    łóÍ˶ÊÊ

  • 100mg

    łÇͧǶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Tesevatinib

CAS No. :781613-23-8
Formula : C24H25Cl2FN4O2
M.W : 491.39
SMILES Code : CN1C[C@@]2([H])[C@@](C[C@@H](COC3=CC4=NC=NC(NC5=CC=C(Cl)C(Cl)=C5F)=C4C=C3OC)C2)([H])C1
Synonyms :
EXEL-7647; XL647; KD-019
MDL No. :MFCD22124889
InChI Key :HVXKQKFEHMGHSL-GOOCMWNKSA-N
Pubchem ID :10458325

Safety of Tesevatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tesevatinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00364780 Non-small-cell Lung Cancer PHASE2 COMPLETED 2025-08-10 Hematology Oncology Associates... More >> of the Treasure Coast, Port Saint Lucie, Florida, 34952, United States|University of Chicago, Chicago, Illinois, 60637, United States|Carle Cancer Center, Urbana, Illinois, 61801, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Wayne University, Wertz Clinical Cancer Center, Karmanos Center, Detroit, Michigan, 48201, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States|Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States Less <<
NCT00086528 Cancer PHASE1 COMPLETED 2025-11-07 Stanford University Medical Ce... More >>nter, Stanford, California, 94305, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States Less <<
NCT00336765 Cancer PHASE1 COMPLETED 2025-09-10 Stanford University Medical Ce... More >>nter, Stanford, California, 94305, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States Less <<
NCT02844439 Glioblastoma|Recurrent Gliobla... More >>stoma|Brain Tumor Less << PHASE2 COMPLETED 2020-04-30 Center for Neurosciences, Tucs... More >>on, Arizona, 85718, United States|City of Hope, Duarte, California, 91010, United States|University of California, San Francisco (UCSF), San Francisco, California, 94143, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States Less <<
NCT02616393 Non-Small Cell Lung Cancer|Lep... More >>tomeningeal Metastases|Brain Metastases Less << PHASE2 COMPLETED 2018-04-03 Beverly Hills Cancer Center, B... More >>everly Hills, California, 90211, United States|USC Norris Oncology/Hematology Newport Beach, Newport Beach, California, 92663, United States|John Wayne Cancer Institute, Santa Monica, California, 90404, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|UT M.D. Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT03096080 Polycystic Kidney, Autosomal R... More >>ecessive Less << PHASE1 COMPLETED 2019-09-30 Children's Hospital of Philade... More >>lphia, Philadelphia, Pennsylvania, 19104, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT00522145 Carcinoma, Non-Small-Cell Lung PHASE2 COMPLETED 2025-02-10 Ronald Yanagihara, Gilroy, Cal... More >>ifornia, 95020, United States|University of California Davis Cancer Center, Sacramento, California, 95817, United States|Oncology Division and General Clincial Research, Stanford University Medical Center, Stanford, California, 94305, United States|Cancer Care Center, Inc. P.C., New Albany, Indiana, 47150, United States|Washington County Hospital, The Center for Clinical Research, Hagerstown, Maryland, 21740, United States|Wayne State University, Wertz Clinical Cancer Center, Karmanos Center, Detroit, Michigan, 48201, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|New Bern Cancer Care Oncology, New Bern, North Carolina, 28560, United States|Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States|Signal Point Clinical Research Center, Middletown, Ohio, 45042, United States Less <<
NCT01559363 Polycystic Kidney, Autosomal D... More >>ominant Less << PHASE1|PHASE2 COMPLETED 2019-02-08 UCLA Medical Center, Los Angel... More >>es, California, 90025, United States|University of Colorado Denver, Denver, Colorado, 80045, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|New York University School of Medicine, New York, New York, 10016, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, 78215, United States|University of Virginia - Nephrology Clinical Research Center, Charlottesville, Virginia, 22908, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.18mL

2.04mL

1.02mL

20.35mL

4.07mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories